title: [Detection and clinical significance of CYFRA21-1 in serum of laryngeal carcinoma patients].
abstract: OBJECTIVE
  To study the relationship between the overexpression of CYFRA21-1 in the serum of laryngeal cracinoma patients and the associated clinical feature.
  
  
  METHODS
  The serum level of CYFRA21-1 were determined by ELISA in 25 laryngeal carcinoma patients preoperatively and postoperatively. 20 laryngeal benign diseases are as control group.
  
  
  RESULTS
  Positive rate was 60% for serum of CYFRA21-1 in the laryngeal carcinoma patiens. The mean serum level for CYFRA21-1 in laryngeal carcinoma patients preoperatively (5.14 +/- 1.82) micrograms/L was significantly elevated than in control group (2.17 +/- 0.68 micrograms/L). The Serum level of CYFRA21-1 1 were significantly declined after surgery under normal level. Serum level of CYFRA21-1 went up once ogain in 2 recurrence patients. There was no correlation between serum level of CYFRA21-1 with age, sex and site in the laryngeal carcinoma patients. There were correlations between the serum level of CYFRA21-1 with clinical stage, pathological grading and lymphatic matatasis. Level of CYFRA21-1 was higher in poorly differentiated.
  
  
  CONCLUSIONS
  The study suggests that serem CYFRA21-1 level could be a useful tumor marker for diagnosis, progenosis and follow-up after surgery in laryngeal carcinomas.
authors.affiliation: Department of Otorhinolargology, Tangdu Hospital, Fourth Millitary Medical University, Xi'an 710038.
authors.forename: Rong
authors.initials: R
authors.lastname: Luo
authors.forename: Guize
authors.initials: G
authors.lastname: Li
authors.forename: Chunsheng
authors.initials: C
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D004938:Esophageal Neoplasms / Q000097:blood* / Q000601:surgery; D005260:Female; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1; D007633:Keratins